Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.82 |
| ▸ | EGFR | P00533 | 7/20 | 0.82 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18600659 | 1.00 | BTK (0.82) | BTKEGFRSRC | |
| SCHEMBL19997537 | 0.93 | BTK (0.79) | BTKEGFRSRC | |
| SCHEMBL15472582 | 0.90 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL15763030 | 0.90 | BTK (0.75) | BTKEGFRSRC | |
| SCHEMBL15763031 | 0.90 | BTK (0.75) | BTKEGFRSRC | |
| SCHEMBL15756482 | 0.90 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL15669774 | 0.90 | BTK (1.00) | BTKEGFRSRC | |
| SCHEMBL16338332 | 0.89 | BTK (0.67) | BTKEGFRSRC | |
| SCHEMBL18472776 | 0.89 | BTK (0.85) | BTKEGFRSRC | |
| SCHEMBL18853844 | 0.89 | BTK (0.85) | BTKEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| EP-3402503-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | Acerta Pharma B.V. (NL) | 2018-11-21 | — | — | EP | disclosed |
| US-10112922-B2 | Inhibitor of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-10-30 | — | — | US | disclosed |
| WO-2017122175-A1 | THERAPEUTIC COMBINATIONS OF AN ANTIFOLATE AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-07-20 | — | — | WO | disclosed |
| US-20170144986-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-05-25 | — | — | US | disclosed |
| EP-3141546-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | Centaurus Biopharma Co., Ltd. (CN) | 2017-03-15 | — | — | EP | disclosed |
| WO-2017033113-A1 | THERAPEUTIC COMBINATIONS OF A MEK INHIBITOR AND A BTK INHIBITOR | ACERTA PHARMA B.V. (NL) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017025814-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016128912-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR, AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016087994-A1 | BTK INHIBITORS TO TREAT SOLID TUMORS THROUGH MODULATION OF THE TUMOR MICROENVIRONMENT | ACERTA PHARMA B.V. (NL) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016024231-A1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA B.V. (NL) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016020901-A1 | METHODS OF TREATING CANCERS, IMMUNE AND AUTOIMMUNE DISEASES, AND INFLAMMATORY DISEASES BASED ON BTK OCCUPANCY AND BTK RESYNTHESIS RATE | ACERTA PHARMA B.V. (NL) | 2016-02-11 | — | — | WO | disclosed |
| US-20150005277-A1 | Protein Kinase Inhibitors and Uses Thereof | BEIGENE, LTD. (KY) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144986-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885EGFR 618/4885SRC 6/4885 |
| US-20150005277-A1 | Protein Kinase Inhibitors and Uses Thereof | BTK, ABL1, PRKACA | BTK 1/4885EGFR 560/4885SRC 11/4885 |
| US-20200069796-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor | BTK, JAK1, PDCD1 | BTK 1/4885EGFR 336/4885SRC 47/4885 |
| US-10112922-B2 | Inhibitor of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885EGFR 618/4885SRC 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.